Bayer receives the green light for cardiac medication - hope for patients!

Bayer receives the green light for cardiac medication - hope for patients!

The German Pharmaceutical Bayer has made decisive progress in the treatment of heart diseases by receiving approval for the heart medication Acoramidis (marked as Beyonttra) in the European Union. According to information from OE24, this drug is used in particular for adult patients with transthyretin-amyloidosis and cardiac participation (attracted CM), a merciless disease that damages the heart muscle and is often associated with an alarming poor forecast for those affected.

innovative therapy against heart diseases

acoramidis has shown significant positive results in the decisive phase III study in relation to cardiovascular endpoints such as mortality and hospital admissions. These results emphasize the urgency and importance of the treatment of this deteriorating disease. Clinical progress comes at a critical time, because Bayer only acquired the exclusive marketing rights for Europe in March 2024, as confirmed by Bayer itself.

Analysts see enormous sales potential in the new drug. According to Richard Vosser from JPmorgan, Acoramidis in Europe could reach top sales of around 260 million euros by 2030. Bayer, on the other hand, estimates the blockbuster potential of the drug over a billion euros per year. These income could be particularly important to compensate for the declines in previous top sellers such as Xarelto in the company's pharmaceutical portfolio. Bayer comes under pressure due to high debts and persistent glyphosate legal disputes. The upcoming business figures that Bayer would like to present at the beginning of March will be crucial for the further development of the company and its medication strategy, as can be seen from various sources.